Billionaire George Soros' Fund Bought These 3 Pharma Stocks: Should You?
Billionaire George Soros is an iconic figure in the world of investing because of his unique ability to consistently beat the broader markets. As such, the quarterly 13F filings of his namesake fund, Soros Fund Management, are must-read material for any serious investor.
The latest 13F filings for the second-quarter of 2017, for example, reveal that the Soros Fund upped its stake in the antisense drugmaker Ionis Pharmaceuticals (NASDAQ: IONS), and initiated positions in the rare disease specialists Alnylam Pharmaceuticals (NASDAQ: ALNY) and BioMarin Pharmaceutical (NASDAQ: BMRN) over the three-month period. As the Soros Fund Management has a fairly strong track record of picking winning pharmaceutical stocks, I think it's worthwhile to consider if these three mid-cap biotech stocks might be particularly strong buys right now. Let's dig in to find out.
Image source: Getty Images.
Source: Fool.com
BioMarin Pharmaceutical Inc. Stock
With 20 Buy predictions and not the single Sell prediction the community is currently very high on BioMarin Pharmaceutical Inc..
As a result the target price of 102 € shows a positive potential of 45.84% compared to the current price of 69.94 € for BioMarin Pharmaceutical Inc..
